Thermo Fisher Scientific (BSP:TMOS34) Notes Receivable: R$0 Mil (As of Mar. 2026)


BSP:TMOS34 Thermo Fisher Scientific Inc BSP:TMOS34
74 GF Score
Price R$54.84
GF Value R$62.34
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Thermo Fisher Scientific Notes Receivable?

Thermo Fisher Scientific BSP:TMOS34 -0.20% 74 Notes Receivable is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$62.34 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Thermo Fisher Scientific's Notes Receivable for the quarter that ended in Mar. 2026 was R$0 Mil.

Thermo Fisher Scientific Notes Receivable Related Terms

Thermo Fisher Scientific Notes Receivable Historical Data

* Premium members only.

The historical data trend for Thermo Fisher Scientific's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thermo Fisher Scientific Notes Receivable Chart

Thermo Fisher Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Thermo Fisher Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:TMOS34
74GF Score
Thermo Fisher Scientific Inc BSP:TMOS34
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thermo Fisher Scientific Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of R$0 Mil mean?
Thermo Fisher Scientific (BSP:TMOS34) has a Notes Receivable of R$0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Thermo Fisher Scientific and its competitors.
Is Thermo Fisher Scientific's Notes Receivable too high?
Thermo Fisher Scientific's current Notes Receivable is R$0 Mil. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Notes Receivable compare to DHR and IDXX?
Thermo Fisher Scientific's Notes Receivable of R$0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Thermo Fisher Scientific and its competitors. Thermo Fisher Scientific's current Notes Receivable is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$62.34, compared to a current price of R$54.84 — trading 12% below its estimated fair value. The current Notes Receivable is R$0 Mil. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Notes Receivable is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?

Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued. The current stock price of R$54.84 is trading 12% below its estimated GF Value™ of R$62.34. GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.

Key valuation signals for BSP:TMOS34:

  • Notes Receivable: R$0 Mil
  • GF Value™: R$62.34 vs. price of R$54.84 (12% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Thermo Fisher Scientific Business Description

Address 168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score

Get the complete analysis for BSP:TMOS34

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$54.84
Price
R$62.34
GF Value